
Opinion|Videos|April 1, 2024
Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM
Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Unexpected Benefits, Unexpected Limits: The Changing Landscape of GLP-1 Research
2
FDA Notifies Flu Vaccine Makers to Add Warning for Increased Febrile Seizure Risk in Young Children Day Following Vaccination
3
Phase 3 MajesTEC-9 Trial Shows Survival Benefit With Teclistamab in Multiple Myeloma
4
Empowering Patients With Complex Regimens: The Pharmacist’s Role in Managing Polypharmacy
5
















































































































































































































